Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc. (DCPH) Stock Competitors & Peer Comparison
See (DCPH) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DCPH | $25.59 | +0.08% | 2.2B | -11.58 | -$2.21 | N/A |
| ZTS | $152.12 | -0.46% | 67.7B | 27.34 | $5.56 | +1.27% |
| TAK | $14.48 | -1.19% | 45.7B | 62.91 | $0.23 | +4.07% |
| HLN | $9.88 | +0.30% | 44.4B | 23.52 | $0.42 | +1.71% |
| TEVA | $16.54 | +1.29% | 19B | -14.39 | -$1.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $132.14 | +0.38% | 13.1B | 44.81 | $2.95 | N/A |
| RDY | $14.67 | -0.27% | 12.2B | 18.56 | $0.79 | +0.50% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| VTRS | $9.41 | +0.64% | 11B | -2.96 | -$3.18 | +5.12% |
Stock Comparison
DCPH vs ZTS Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ZTS has a market cap of 67.7B. Regarding current trading prices, DCPH is priced at $25.59, while ZTS trades at $152.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ZTS's P/E ratio is 27.34. In terms of profitability, DCPH's ROE is -0.28%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, DCPH is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check ZTS's competition here
DCPH vs TAK Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, TAK has a market cap of 45.7B. Regarding current trading prices, DCPH is priced at $25.59, while TAK trades at $14.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas TAK's P/E ratio is 62.91. In terms of profitability, DCPH's ROE is -0.28%, compared to TAK's ROE of +0.04%. Regarding short-term risk, DCPH is less volatile compared to TAK. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check TAK's competition here
DCPH vs HLN Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, HLN has a market cap of 44.4B. Regarding current trading prices, DCPH is priced at $25.59, while HLN trades at $9.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas HLN's P/E ratio is 23.52. In terms of profitability, DCPH's ROE is -0.28%, compared to HLN's ROE of +0.09%. Regarding short-term risk, DCPH is less volatile compared to HLN. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check HLN's competition here
DCPH vs TEVA Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, TEVA has a market cap of 19B. Regarding current trading prices, DCPH is priced at $25.59, while TEVA trades at $16.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas TEVA's P/E ratio is -14.39. In terms of profitability, DCPH's ROE is -0.28%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, DCPH is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check TEVA's competition here
DCPH vs ITCI Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, DCPH is priced at $25.59, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ITCI's P/E ratio is -180.64. In terms of profitability, DCPH's ROE is -0.28%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, DCPH is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for DCPH.Check ITCI's competition here
DCPH vs NBIX Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, NBIX has a market cap of 13.1B. Regarding current trading prices, DCPH is priced at $25.59, while NBIX trades at $132.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas NBIX's P/E ratio is 44.81. In terms of profitability, DCPH's ROE is -0.28%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, DCPH is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check NBIX's competition here
DCPH vs RDY Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, RDY has a market cap of 12.2B. Regarding current trading prices, DCPH is priced at $25.59, while RDY trades at $14.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas RDY's P/E ratio is 18.56. In terms of profitability, DCPH's ROE is -0.28%, compared to RDY's ROE of +0.18%. Regarding short-term risk, DCPH is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check RDY's competition here
DCPH vs CTLT Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, DCPH is priced at $25.59, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas CTLT's P/E ratio is -27.84. In terms of profitability, DCPH's ROE is -0.28%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, DCPH is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for DCPH.Check CTLT's competition here
DCPH vs VTRS Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, VTRS has a market cap of 11B. Regarding current trading prices, DCPH is priced at $25.59, while VTRS trades at $9.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas VTRS's P/E ratio is -2.96. In terms of profitability, DCPH's ROE is -0.28%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, DCPH is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check VTRS's competition here
DCPH vs RGC Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, RGC has a market cap of 7.4B. Regarding current trading prices, DCPH is priced at $25.59, while RGC trades at $15.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas RGC's P/E ratio is -1505.00. In terms of profitability, DCPH's ROE is -0.28%, compared to RGC's ROE of -0.50%. Regarding short-term risk, DCPH is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check RGC's competition here
DCPH vs ELAN Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ELAN has a market cap of 7.4B. Regarding current trading prices, DCPH is priced at $25.59, while ELAN trades at $14.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ELAN's P/E ratio is 19.91. In terms of profitability, DCPH's ROE is -0.28%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, DCPH is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check ELAN's competition here
DCPH vs LNTH Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, LNTH has a market cap of 5B. Regarding current trading prices, DCPH is priced at $25.59, while LNTH trades at $72.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas LNTH's P/E ratio is 20.78. In terms of profitability, DCPH's ROE is -0.28%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, DCPH is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check LNTH's competition here
DCPH vs PRGO Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, PRGO has a market cap of 3.9B. Regarding current trading prices, DCPH is priced at $25.59, while PRGO trades at $28.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas PRGO's P/E ratio is -23.68. In terms of profitability, DCPH's ROE is -0.28%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, DCPH is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check PRGO's competition here
DCPH vs HCM Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, HCM has a market cap of 3.1B. Regarding current trading prices, DCPH is priced at $25.59, while HCM trades at $17.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas HCM's P/E ratio is 88.05. In terms of profitability, DCPH's ROE is -0.28%, compared to HCM's ROE of +0.05%. Regarding short-term risk, DCPH is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check HCM's competition here
DCPH vs ALVOW Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ALVOW has a market cap of 3.1B. Regarding current trading prices, DCPH is priced at $25.59, while ALVOW trades at $2.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ALVOW's P/E ratio is N/A. In terms of profitability, DCPH's ROE is -0.28%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, DCPH is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check ALVOW's competition here
DCPH vs ALVO Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ALVO has a market cap of 2.9B. Regarding current trading prices, DCPH is priced at $25.59, while ALVO trades at $9.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ALVO's P/E ratio is 25.97. In terms of profitability, DCPH's ROE is -0.28%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, DCPH is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check ALVO's competition here
DCPH vs AMRX Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, AMRX has a market cap of 2.5B. Regarding current trading prices, DCPH is priced at $25.59, while AMRX trades at $8.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas AMRX's P/E ratio is -201.62. In terms of profitability, DCPH's ROE is -0.28%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, DCPH is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check AMRX's competition here
DCPH vs BHC Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, BHC has a market cap of 2.5B. Regarding current trading prices, DCPH is priced at $25.59, while BHC trades at $6.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas BHC's P/E ratio is -56.50. In terms of profitability, DCPH's ROE is -0.28%, compared to BHC's ROE of +0.05%. Regarding short-term risk, DCPH is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check BHC's competition here
DCPH vs INDV Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, INDV has a market cap of 2.1B. Regarding current trading prices, DCPH is priced at $25.59, while INDV trades at $17.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas INDV's P/E ratio is -342.80. In terms of profitability, DCPH's ROE is -0.28%, compared to INDV's ROE of -0.01%. Regarding short-term risk, DCPH is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check INDV's competition here
DCPH vs BGM Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, BGM has a market cap of 2.1B. Regarding current trading prices, DCPH is priced at $25.59, while BGM trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas BGM's P/E ratio is -52.25. In terms of profitability, DCPH's ROE is -0.28%, compared to BGM's ROE of -0.03%. Regarding short-term risk, DCPH is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check BGM's competition here
DCPH vs EMBCV Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, DCPH is priced at $25.59, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas EMBCV's P/E ratio is N/A. In terms of profitability, DCPH's ROE is -0.28%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, DCPH is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check EMBCV's competition here
DCPH vs SUPN Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, SUPN has a market cap of 1.9B. Regarding current trading prices, DCPH is priced at $25.59, while SUPN trades at $33.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas SUPN's P/E ratio is 30.25. In terms of profitability, DCPH's ROE is -0.28%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, DCPH is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check SUPN's competition here
DCPH vs TARO Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, DCPH is priced at $25.59, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas TARO's P/E ratio is 30.05. In terms of profitability, DCPH's ROE is -0.28%, compared to TARO's ROE of +0.02%. Regarding short-term risk, DCPH is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for DCPH.Check TARO's competition here
DCPH vs EVO Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, EVO has a market cap of 1.5B. Regarding current trading prices, DCPH is priced at $25.59, while EVO trades at $4.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas EVO's P/E ratio is -6.26. In terms of profitability, DCPH's ROE is -0.28%, compared to EVO's ROE of -0.22%. Regarding short-term risk, DCPH is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check EVO's competition here
DCPH vs ANIP Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ANIP has a market cap of 1.5B. Regarding current trading prices, DCPH is priced at $25.59, while ANIP trades at $67.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ANIP's P/E ratio is -57.19. In terms of profitability, DCPH's ROE is -0.28%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, DCPH is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check ANIP's competition here
DCPH vs DVAX Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, DVAX has a market cap of 1.4B. Regarding current trading prices, DCPH is priced at $25.59, while DVAX trades at $11.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas DVAX's P/E ratio is -22.70. In terms of profitability, DCPH's ROE is -0.28%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, DCPH is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check DVAX's competition here
DCPH vs HROW Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, HROW has a market cap of 1.3B. Regarding current trading prices, DCPH is priced at $25.59, while HROW trades at $36.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas HROW's P/E ratio is -59.33. In terms of profitability, DCPH's ROE is -0.28%, compared to HROW's ROE of -0.36%. Regarding short-term risk, DCPH is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check HROW's competition here
DCPH vs FLXN Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, FLXN has a market cap of 1.3B. Regarding current trading prices, DCPH is priced at $25.59, while FLXN trades at $25.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas FLXN's P/E ratio is N/A. In terms of profitability, DCPH's ROE is -0.28%, compared to FLXN's ROE of +6.19%. Regarding short-term risk, DCPH is more volatile compared to FLXN. This indicates potentially higher risk in terms of short-term price fluctuations for DCPH.Check FLXN's competition here
DCPH vs PAHC Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, PAHC has a market cap of 1.2B. Regarding current trading prices, DCPH is priced at $25.59, while PAHC trades at $29.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas PAHC's P/E ratio is 37.41. In terms of profitability, DCPH's ROE is -0.28%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, DCPH is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check PAHC's competition here
DCPH vs AVDL Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, AVDL has a market cap of 1.1B. Regarding current trading prices, DCPH is priced at $25.59, while AVDL trades at $11.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas AVDL's P/E ratio is -42.42. In terms of profitability, DCPH's ROE is -0.28%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, DCPH is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check AVDL's competition here
DCPH vs AMPH Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, DCPH is priced at $25.59, while AMPH trades at $22.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas AMPH's P/E ratio is 8.11. In terms of profitability, DCPH's ROE is -0.28%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, DCPH is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check AMPH's competition here
DCPH vs PCRX Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, DCPH is priced at $25.59, while PCRX trades at $22.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas PCRX's P/E ratio is -10.07. In terms of profitability, DCPH's ROE is -0.28%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, DCPH is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check PCRX's competition here
DCPH vs COLL Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, COLL has a market cap of 1B. Regarding current trading prices, DCPH is priced at $25.59, while COLL trades at $31.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas COLL's P/E ratio is 26.05. In terms of profitability, DCPH's ROE is -0.28%, compared to COLL's ROE of +0.19%. Regarding short-term risk, DCPH is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check COLL's competition here
DCPH vs PETQ Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, DCPH is priced at $25.59, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas PETQ's P/E ratio is 83.73. In terms of profitability, DCPH's ROE is -0.28%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, DCPH is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for DCPH.Check PETQ's competition here
DCPH vs CRON Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, CRON has a market cap of 790.1M. Regarding current trading prices, DCPH is priced at $25.59, while CRON trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas CRON's P/E ratio is 14.64. In terms of profitability, DCPH's ROE is -0.28%, compared to CRON's ROE of +0.05%. Regarding short-term risk, DCPH is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check CRON's competition here
DCPH vs TLRY Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, TLRY has a market cap of 714.7M. Regarding current trading prices, DCPH is priced at $25.59, while TLRY trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas TLRY's P/E ratio is -0.63. In terms of profitability, DCPH's ROE is -0.28%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, DCPH is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check TLRY's competition here
DCPH vs EMBC Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, EMBC has a market cap of 685.5M. Regarding current trading prices, DCPH is priced at $25.59, while EMBC trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas EMBC's P/E ratio is 13.18. In terms of profitability, DCPH's ROE is -0.28%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, DCPH is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check EMBC's competition here
DCPH vs ORGO Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ORGO has a market cap of 638.1M. Regarding current trading prices, DCPH is priced at $25.59, while ORGO trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ORGO's P/E ratio is -31.44. In terms of profitability, DCPH's ROE is -0.28%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, DCPH is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check ORGO's competition here
DCPH vs EOLS Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, EOLS has a market cap of 615.1M. Regarding current trading prices, DCPH is priced at $25.59, while EOLS trades at $9.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas EOLS's P/E ratio is -10.72. In terms of profitability, DCPH's ROE is -0.28%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, DCPH is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check EOLS's competition here
DCPH vs BDSI Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, DCPH is priced at $25.59, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas BDSI's P/E ratio is 6.82. In terms of profitability, DCPH's ROE is -0.28%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, DCPH is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for DCPH.Check BDSI's competition here
DCPH vs SIGA Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, SIGA has a market cap of 510.1M. Regarding current trading prices, DCPH is priced at $25.59, while SIGA trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas SIGA's P/E ratio is 10.66. In terms of profitability, DCPH's ROE is -0.28%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, DCPH is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check SIGA's competition here
DCPH vs KMDA Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, KMDA has a market cap of 443.9M. Regarding current trading prices, DCPH is priced at $25.59, while KMDA trades at $7.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas KMDA's P/E ratio is 27.57. In terms of profitability, DCPH's ROE is -0.28%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, DCPH is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check KMDA's competition here
DCPH vs AQST Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, AQST has a market cap of 412.2M. Regarding current trading prices, DCPH is priced at $25.59, while AQST trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas AQST's P/E ratio is -7.16. In terms of profitability, DCPH's ROE is -0.28%, compared to AQST's ROE of +1.07%. Regarding short-term risk, DCPH is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check AQST's competition here
DCPH vs SNDL Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, SNDL has a market cap of 389.8M. Regarding current trading prices, DCPH is priced at $25.59, while SNDL trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas SNDL's P/E ratio is -5.05. In terms of profitability, DCPH's ROE is -0.28%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, DCPH is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check SNDL's competition here
DCPH vs EBS Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, EBS has a market cap of 388.4M. Regarding current trading prices, DCPH is priced at $25.59, while EBS trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas EBS's P/E ratio is -2.77. In terms of profitability, DCPH's ROE is -0.28%, compared to EBS's ROE of -0.27%. Regarding short-term risk, DCPH is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check EBS's competition here
DCPH vs ALIM Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, DCPH is priced at $25.59, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ALIM's P/E ratio is 5.28. In terms of profitability, DCPH's ROE is -0.28%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, DCPH is less volatile compared to ALIM. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check ALIM's competition here
DCPH vs ESPR Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ESPR has a market cap of 299.3M. Regarding current trading prices, DCPH is priced at $25.59, while ESPR trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ESPR's P/E ratio is -1.78. In terms of profitability, DCPH's ROE is -0.28%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, DCPH is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check ESPR's competition here
DCPH vs TKNO Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, TKNO has a market cap of 276.8M. Regarding current trading prices, DCPH is priced at $25.59, while TKNO trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas TKNO's P/E ratio is -11.26. In terms of profitability, DCPH's ROE is -0.28%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, DCPH is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check TKNO's competition here
DCPH vs LFCR Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, LFCR has a market cap of 275.1M. Regarding current trading prices, DCPH is priced at $25.59, while LFCR trades at $7.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas LFCR's P/E ratio is -5.05. In terms of profitability, DCPH's ROE is -0.28%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, DCPH is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check LFCR's competition here
DCPH vs ACB Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ACB has a market cap of 272.2M. Regarding current trading prices, DCPH is priced at $25.59, while ACB trades at $4.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ACB's P/E ratio is 22.00. In terms of profitability, DCPH's ROE is -0.28%, compared to ACB's ROE of +0.00%. Regarding short-term risk, DCPH is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check ACB's competition here
DCPH vs LNDC Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, DCPH is priced at $25.59, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas LNDC's P/E ratio is -4.04. In terms of profitability, DCPH's ROE is -0.28%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, DCPH is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check LNDC's competition here
DCPH vs ZYBT Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ZYBT has a market cap of 263M. Regarding current trading prices, DCPH is priced at $25.59, while ZYBT trades at $5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ZYBT's P/E ratio is 185.00. In terms of profitability, DCPH's ROE is -0.28%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, DCPH is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check ZYBT's competition here
DCPH vs CGC Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, CGC has a market cap of 235.7M. Regarding current trading prices, DCPH is priced at $25.59, while CGC trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas CGC's P/E ratio is -0.27. In terms of profitability, DCPH's ROE is -0.28%, compared to CGC's ROE of -1.13%. Regarding short-term risk, DCPH is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check CGC's competition here
DCPH vs TYHT Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, DCPH is priced at $25.59, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas TYHT's P/E ratio is -1.61. In terms of profitability, DCPH's ROE is -0.28%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, DCPH is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check TYHT's competition here
DCPH vs OGI Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, OGI has a market cap of 204.8M. Regarding current trading prices, DCPH is priced at $25.59, while OGI trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas OGI's P/E ratio is 11.77. In terms of profitability, DCPH's ROE is -0.28%, compared to OGI's ROE of +0.05%. Regarding short-term risk, DCPH is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check OGI's competition here
DCPH vs SXTC Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, SXTC has a market cap of 184.5M. Regarding current trading prices, DCPH is priced at $25.59, while SXTC trades at $1.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas SXTC's P/E ratio is 0.01. In terms of profitability, DCPH's ROE is -0.28%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, DCPH is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check SXTC's competition here
DCPH vs REPH Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, DCPH is priced at $25.59, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas REPH's P/E ratio is -8.04. In terms of profitability, DCPH's ROE is -0.28%, compared to REPH's ROE of -0.22%. Regarding short-term risk, DCPH is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check REPH's competition here
DCPH vs DERM Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, DERM has a market cap of 176.8M. Regarding current trading prices, DCPH is priced at $25.59, while DERM trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas DERM's P/E ratio is -20.51. In terms of profitability, DCPH's ROE is -0.28%, compared to DERM's ROE of -0.52%. Regarding short-term risk, DCPH is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check DERM's competition here
DCPH vs BIOA Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, BIOA has a market cap of 165.6M. Regarding current trading prices, DCPH is priced at $25.59, while BIOA trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas BIOA's P/E ratio is -2.33. In terms of profitability, DCPH's ROE is -0.28%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, DCPH is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check BIOA's competition here
DCPH vs THTX Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, THTX has a market cap of 145.8M. Regarding current trading prices, DCPH is priced at $25.59, while THTX trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas THTX's P/E ratio is -16.68. In terms of profitability, DCPH's ROE is -0.28%, compared to THTX's ROE of +0.38%. Regarding short-term risk, DCPH is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check THTX's competition here
DCPH vs IRWD Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, IRWD has a market cap of 132.1M. Regarding current trading prices, DCPH is priced at $25.59, while IRWD trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas IRWD's P/E ratio is -4.30. In terms of profitability, DCPH's ROE is -0.28%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, DCPH is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check IRWD's competition here
DCPH vs CRDL Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, CRDL has a market cap of 119M. Regarding current trading prices, DCPH is priced at $25.59, while CRDL trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas CRDL's P/E ratio is -4.24. In terms of profitability, DCPH's ROE is -0.28%, compared to CRDL's ROE of -2.10%. Regarding short-term risk, DCPH is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check CRDL's competition here
DCPH vs SCTL Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, DCPH is priced at $25.59, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas SCTL's P/E ratio is -7.86. In terms of profitability, DCPH's ROE is -0.28%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, DCPH is less volatile compared to SCTL. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check SCTL's competition here
DCPH vs PROC Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, PROC has a market cap of 114M. Regarding current trading prices, DCPH is priced at $25.59, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas PROC's P/E ratio is 1.53. In terms of profitability, DCPH's ROE is -0.28%, compared to PROC's ROE of -2.22%. Regarding short-term risk, DCPH is less volatile compared to PROC. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check PROC's competition here
DCPH vs IXHL Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, IXHL has a market cap of 97.4M. Regarding current trading prices, DCPH is priced at $25.59, while IXHL trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas IXHL's P/E ratio is -0.85. In terms of profitability, DCPH's ROE is -0.28%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, DCPH is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check IXHL's competition here
DCPH vs OPTN Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, DCPH is priced at $25.59, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas OPTN's P/E ratio is -4.42. In terms of profitability, DCPH's ROE is -0.28%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, DCPH is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for DCPH.Check OPTN's competition here
DCPH vs ZOM Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, DCPH is priced at $25.59, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ZOM's P/E ratio is -1.62. In terms of profitability, DCPH's ROE is -0.28%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, DCPH is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check ZOM's competition here
DCPH vs GRVI Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, DCPH is priced at $25.59, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas GRVI's P/E ratio is 26.05. In terms of profitability, DCPH's ROE is -0.28%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, DCPH is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check GRVI's competition here
DCPH vs QNTM Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, QNTM has a market cap of 86.1M. Regarding current trading prices, DCPH is priced at $25.59, while QNTM trades at $25.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas QNTM's P/E ratio is -1.90. In terms of profitability, DCPH's ROE is -0.28%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, DCPH is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check QNTM's competition here
DCPH vs INCR Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, INCR has a market cap of 83.9M. Regarding current trading prices, DCPH is priced at $25.59, while INCR trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas INCR's P/E ratio is -3.50. In terms of profitability, DCPH's ROE is -0.28%, compared to INCR's ROE of -0.07%. Regarding short-term risk, DCPH is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check INCR's competition here
DCPH vs ASRT Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ASRT has a market cap of 70.9M. Regarding current trading prices, DCPH is priced at $25.59, while ASRT trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ASRT's P/E ratio is -2.31. In terms of profitability, DCPH's ROE is -0.28%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, DCPH is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check ASRT's competition here
DCPH vs ZYNE Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, DCPH is priced at $25.59, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, DCPH's ROE is -0.28%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, DCPH is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check ZYNE's competition here
DCPH vs SSIC Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, DCPH is priced at $25.59, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas SSIC's P/E ratio is 11.93. In terms of profitability, DCPH's ROE is -0.28%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, DCPH is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check SSIC's competition here
DCPH vs VLNS Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, DCPH is priced at $25.59, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas VLNS's P/E ratio is -1.03. In terms of profitability, DCPH's ROE is -0.28%, compared to VLNS's ROE of N/A. Regarding short-term risk, DCPH is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check VLNS's competition here
DCPH vs CPIX Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, CPIX has a market cap of 52.6M. Regarding current trading prices, DCPH is priced at $25.59, while CPIX trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas CPIX's P/E ratio is -14.65. In terms of profitability, DCPH's ROE is -0.28%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, DCPH is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check CPIX's competition here
DCPH vs KALA Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, KALA has a market cap of 52.2M. Regarding current trading prices, DCPH is priced at $25.59, while KALA trades at $8.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas KALA's P/E ratio is -1.10. In terms of profitability, DCPH's ROE is -0.28%, compared to KALA's ROE of -3.69%. Regarding short-term risk, DCPH is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check KALA's competition here
DCPH vs JUPW Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, DCPH is priced at $25.59, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas JUPW's P/E ratio is -2.41. In terms of profitability, DCPH's ROE is -0.28%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, DCPH is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check JUPW's competition here
DCPH vs EGRX Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, EGRX has a market cap of 47.8M. Regarding current trading prices, DCPH is priced at $25.59, while EGRX trades at $3.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas EGRX's P/E ratio is 4.34. In terms of profitability, DCPH's ROE is -0.28%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, DCPH is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check EGRX's competition here
DCPH vs QLI Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, DCPH is priced at $25.59, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas QLI's P/E ratio is -4.92. In terms of profitability, DCPH's ROE is -0.28%, compared to QLI's ROE of -0.16%. Regarding short-term risk, DCPH is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for DCPH.Check QLI's competition here
DCPH vs RMTI Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, RMTI has a market cap of 36.6M. Regarding current trading prices, DCPH is priced at $25.59, while RMTI trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas RMTI's P/E ratio is -107.00. In terms of profitability, DCPH's ROE is -0.28%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, DCPH is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check RMTI's competition here
DCPH vs HEXO Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, DCPH is priced at $25.59, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas HEXO's P/E ratio is -0.26. In terms of profitability, DCPH's ROE is -0.28%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, DCPH is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check HEXO's competition here
DCPH vs SCYX Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, SCYX has a market cap of 28.5M. Regarding current trading prices, DCPH is priced at $25.59, while SCYX trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas SCYX's P/E ratio is -1.30. In terms of profitability, DCPH's ROE is -0.28%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, DCPH is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check SCYX's competition here
DCPH vs CYTH Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, DCPH is priced at $25.59, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas CYTH's P/E ratio is -0.80. In terms of profitability, DCPH's ROE is -0.28%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, DCPH is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for DCPH.Check CYTH's competition here
DCPH vs BFRIW Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, BFRIW has a market cap of 21.9M. Regarding current trading prices, DCPH is priced at $25.59, while BFRIW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas BFRIW's P/E ratio is -0.15. In terms of profitability, DCPH's ROE is -0.28%, compared to BFRIW's ROE of -2.16%. Regarding short-term risk, DCPH is less volatile compared to BFRIW. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check BFRIW's competition here
DCPH vs COSM Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, COSM has a market cap of 20.4M. Regarding current trading prices, DCPH is priced at $25.59, while COSM trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas COSM's P/E ratio is -0.64. In terms of profitability, DCPH's ROE is -0.28%, compared to COSM's ROE of -0.51%. Regarding short-term risk, DCPH is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check COSM's competition here
DCPH vs PRPH Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, PRPH has a market cap of 19.4M. Regarding current trading prices, DCPH is priced at $25.59, while PRPH trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas PRPH's P/E ratio is -0.21. In terms of profitability, DCPH's ROE is -0.28%, compared to PRPH's ROE of -1.65%. Regarding short-term risk, DCPH is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check PRPH's competition here
DCPH vs GELS Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, GELS has a market cap of 19.2M. Regarding current trading prices, DCPH is priced at $25.59, while GELS trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas GELS's P/E ratio is -5.46. In terms of profitability, DCPH's ROE is -0.28%, compared to GELS's ROE of -0.07%. Regarding short-term risk, DCPH is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check GELS's competition here
DCPH vs DRRX Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, DRRX has a market cap of 17.6M. Regarding current trading prices, DCPH is priced at $25.59, while DRRX trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas DRRX's P/E ratio is -1.18. In terms of profitability, DCPH's ROE is -0.28%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, DCPH is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check DRRX's competition here
DCPH vs AYTU Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, AYTU has a market cap of 16.2M. Regarding current trading prices, DCPH is priced at $25.59, while AYTU trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas AYTU's P/E ratio is -1.76. In terms of profitability, DCPH's ROE is -0.28%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, DCPH is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check AYTU's competition here
DCPH vs ACRX Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, DCPH is priced at $25.59, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas ACRX's P/E ratio is -0.31. In terms of profitability, DCPH's ROE is -0.28%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, DCPH is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check ACRX's competition here
DCPH vs FLGC Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, FLGC has a market cap of 13.9M. Regarding current trading prices, DCPH is priced at $25.59, while FLGC trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas FLGC's P/E ratio is -0.64. In terms of profitability, DCPH's ROE is -0.28%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, DCPH is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check FLGC's competition here
DCPH vs TXMD Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, TXMD has a market cap of 13.8M. Regarding current trading prices, DCPH is priced at $25.59, while TXMD trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas TXMD's P/E ratio is -6.26. In terms of profitability, DCPH's ROE is -0.28%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, DCPH is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check TXMD's competition here
DCPH vs BFRI Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, BFRI has a market cap of 10.8M. Regarding current trading prices, DCPH is priced at $25.59, while BFRI trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas BFRI's P/E ratio is -1.32. In terms of profitability, DCPH's ROE is -0.28%, compared to BFRI's ROE of -2.16%. Regarding short-term risk, DCPH is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check BFRI's competition here
DCPH vs AGRX Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, DCPH is priced at $25.59, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas AGRX's P/E ratio is -0.89. In terms of profitability, DCPH's ROE is -0.28%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, DCPH is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check AGRX's competition here
DCPH vs TLPH Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, TLPH has a market cap of 8.7M. Regarding current trading prices, DCPH is priced at $25.59, while TLPH trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas TLPH's P/E ratio is -0.96. In terms of profitability, DCPH's ROE is -0.28%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, DCPH is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check TLPH's competition here
DCPH vs IMCC Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, IMCC has a market cap of 8.7M. Regarding current trading prices, DCPH is priced at $25.59, while IMCC trades at $2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas IMCC's P/E ratio is -2.01. In terms of profitability, DCPH's ROE is -0.28%, compared to IMCC's ROE of -0.79%. Regarding short-term risk, DCPH is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check IMCC's competition here
DCPH vs YCBD Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, YCBD has a market cap of 8.5M. Regarding current trading prices, DCPH is priced at $25.59, while YCBD trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas YCBD's P/E ratio is 0.01. In terms of profitability, DCPH's ROE is -0.28%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, DCPH is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check YCBD's competition here
DCPH vs NLTX Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, DCPH is priced at $25.59, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas NLTX's P/E ratio is -0.28. In terms of profitability, DCPH's ROE is -0.28%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, DCPH is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check NLTX's competition here
DCPH vs SISI Comparison July 2025
DCPH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DCPH stands at 2.2B. In comparison, SISI has a market cap of 8M. Regarding current trading prices, DCPH is priced at $25.59, while SISI trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DCPH currently has a P/E ratio of -11.58, whereas SISI's P/E ratio is N/A. In terms of profitability, DCPH's ROE is -0.28%, compared to SISI's ROE of -1.41%. Regarding short-term risk, DCPH is less volatile compared to SISI. This indicates potentially lower risk in terms of short-term price fluctuations for DCPH.Check SISI's competition here